S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
NASDAQ:DMAC

DiaMedica Therapeutics - DMAC Stock Forecast, Price & News

$1.69
-0.01 (-0.59%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.66
$1.72
50-Day Range
$1.26
$2.49
52-Week Range
$1.15
$4.82
Volume
57,731 shs
Average Volume
143,521 shs
Market Capitalization
$44.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67

DiaMedica Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
767.9% Upside
$14.67 Price Target
Short Interest
Healthy
0.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$276,605 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

384th out of 1,283 stocks

Pharmaceutical Preparations Industry

168th out of 615 stocks

DMAC stock logo

About DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ:DMAC traded down $0.01 during midday trading on Friday, hitting $1.69. The company's stock had a trading volume of 57,731 shares, compared to its average volume of 143,521. The business's fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $2.32. DiaMedica Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.82. The firm has a market capitalization of $44.68 million, a price-to-earnings ratio of -2.91 and a beta of 2.07.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.07. During the same quarter in the previous year, the business posted ($0.19) earnings per share. Analysts anticipate that DiaMedica Therapeutics will post -0.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DMAC. Craig Hallum dropped their price objective on shares of DiaMedica Therapeutics from $18.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, July 7th. Lake Street Capital lowered their target price on shares of DiaMedica Therapeutics from $14.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, July 7th. Finally, Oppenheimer lowered shares of DiaMedica Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, July 7th.

Insider Activity

In other news, major shareholder Koch Thomas Von bought 207,974 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, July 8th. The shares were purchased at an average price of $1.33 per share, with a total value of $276,605.42. Following the completion of the acquisition, the insider now directly owns 2,855,827 shares in the company, valued at $3,798,249.91. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.60% of the company's stock.

Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Stock News Headlines

DiaMedica Therapeutics appoints chief medical officer
See More Headlines
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Company Calendar

Last Earnings
11/10/2021
Today
8/07/2022
Next Earnings (Confirmed)
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DMAC
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.67
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+767.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-13,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.67 per share

Miscellaneous

Free Float
24,962,000
Market Cap
$44.68 million
Optionable
Not Optionable
Beta
2.07














DMAC Stock - Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DiaMedica Therapeutics stock.
View analyst ratings for DiaMedica Therapeutics
or view top-rated stocks.

What is DiaMedica Therapeutics' stock price forecast for 2022?

4 analysts have issued 12-month price objectives for DiaMedica Therapeutics' stock. Their DMAC stock forecasts range from $8.00 to $24.00. On average, they expect DiaMedica Therapeutics' stock price to reach $14.67 in the next year. This suggests a possible upside of 767.9% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics
or view top-rated stocks among Wall Street analysts.

How has DiaMedica Therapeutics' stock price performed in 2022?

DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of the year. Since then, DMAC stock has decreased by 54.7% and is now trading at $1.69.
View the best growth stocks for 2022 here
.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for DiaMedica Therapeutics
.

How can I listen to DiaMedica Therapeutics' earnings call?

DiaMedica Therapeutics will be holding an earnings conference call on Thursday, August 11th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-770-2030 with passcode "4814247".

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) released its earnings results on Wednesday, November, 10th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. During the same period in the previous year, the company posted ($0.19) EPS.

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $1.69.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $44.68 million. The company earns $-13,590,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does DiaMedica Therapeutics have?

DiaMedica Therapeutics employs 14 workers across the globe.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for DiaMedica Therapeutics is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com.

This page (NASDAQ:DMAC) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.